Double-blind study of modified neurotoxin in motor neuron disease.
In a double-blind study, we evaluated the intramuscular administration of modified neurotoxin in 48 patients who were treated for 6 months. There was no evidence to support claims that patients receive any benefit from the neurotoxin. A significant number of patients had minor functional improvement, often of a transient nature, but these manifestations were more common in the placebo-treated patients than in those receiving neurotoxin. These variations in the course of motor neuron disease have not been stressed in the previous literature.
D002038:Bungarotoxins / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003039:Cobra Neurotoxin Proteins / Q000627:therapeutic use*; D004311:Double-Blind Method; D004546:Elapid Venoms / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009046:Motor Neurons; D009468:Neuromuscular Diseases / Q000188:drug therapy*; D009498:Neurotoxins / Q000627:therapeutic use*; D010919:Placebos
D002038:Bungarotoxins; D003039:Cobra Neurotoxin Proteins; D004546:Elapid Venoms; D009498:Neurotoxins; D010919:Placebos